Preparation and immunogenicity of vaccine Ac NFU1 (S-) MRC towards the prevention of herpes genitalis.

Publisher Website
Google Scholar
Abstract
A subunit antigenoid vaccine, Ac NFU1 (S-) MRC, was used to prevent primary herpes genitalis in 60 subjects considered at risk of this infection. There was no evidence of serious local or general side effects. Neutralizing antibody responses were detected in 59 and 90% of subjects receiving the low and high doses of vaccine, respectively; immunoprecipitating antibody was detected in 23 and 43% of subjects receiving the low and high doses, respectively. After a mean follow-up period of 18 mo., none of the vaccinated subjects contracted herpes genitalis after completing the vaccination course.
Keywords

This publication has 28 references indexed in Scilit: